Clinical Trials
2 trialsNCT00230178 2010-01-12
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Sanofi
Phase 3 Completed
NCT00230217 2009-03-30
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Sanofi
Phase 4 Completed